REDUCTION IN THE BIOLOGICAL POTENCY OF HUMAN CHORIONIC GONADOTROPHIN BY ANTISERA TO HUMAN MENOPAUSAL GONADOTROPHIN

in Journal of Endocrinology
Authors:
C. E. WILDE
Search for other papers by C. E. WILDE in
Current site
Google Scholar
PubMed
Close
,
K. D. BAGSHAWE
Search for other papers by K. D. BAGSHAWE in
Current site
Google Scholar
PubMed
Close
,
ANNE DREWE
Search for other papers by ANNE DREWE in
Current site
Google Scholar
PubMed
Close
, and
WENDY PALLAS
Search for other papers by WENDY PALLAS in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

Quantitative biological and immunological assays for gonadotrophins are used routinely in this laboratory to provide an index of tumour activity in patients with chorioncarcinoma. Such tumours produce chorionic gonadotrophin (HCG) and this hormone is excreted in the urine together with the small amount of gonadotrophin of pituitary origin (HMG) which is always present in normal adult urines. The assay methods for gonadotrophins which are at present available do not allow differentiation between HCG and the luteinizing component of HMG. At the beginning of treatment when the rate of HCG excretion is usually high, this lack of specificity is not important, but towards the end of treatment when gonadotrophin levels approach the normal it is difficult to detect with certainty the slight HCG excess which will indicate the presence of a small amount of viable tumour tissue. In order to have a precise indication of complete destruction of the tumour, it

 

  • Collapse
  • Expand